Bosch, X, Marrugat, J, Sanchis, J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev 2013; 11: CD002130.
Silvain, J, et al. Thrombus composition in sudden cardiac death from acute myocardial infarction. Resuscitation 2017; 113: 108–114.
Iwata, H, et al. Impact of primitive cells in intracoronary thrombi on lesion prognosis: temporal analysis of cellular constituents of thrombotic material obtained from patients with acute coronary syndrome. Heart (British Cardiac Society) 2010; 96: 748–755.
Yunoki, K, et al. Thrombus aspiration therapy and coronary thrombus components in patients with acute ST-elevation myocardial infarction. Journal of Atherosclerosis and Thrombosis 2013; 20: 524–537.
De Luca, G, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. Journal of Thrombosis and Haemostasis 2011; 9: 2361–2370.
De Luca, G, et al. Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation). The American Journal of Cardiology 2015; 115: 711–715.
Xu, Q, Yin, J, Si, LY. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI. International Journal of Cardiology 2012; 162: 210–219.
Dudek, D, et al. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab - EUROTRANSFER Registry. American Heart Journal 2008; 156: 1147–1154.
Li, J, et al. RUC-4: A novel alphaIIbbeta3 antagonist for pre-hospital therapy of myocardial infarction. Arteriosclerosis, Thrombosis, and Vascular Biology 2014; 34: 2321–2329.
Blue, R, et al. Application of high throughput screening to identify a novel αIIb-specific small molecule inhibitor of αIIbβ3-mediated platelet Interaction with fibrinogen. Blood 2008; 111: 1248–1256.
Blue, R, et al. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel αIIb-specific αIIbβ3 antagonist. Blood 2009; 114: 195–201.
Zhu, J, et al. Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening. Blood 2010; 116: 5050–5059.
Zhu, J, et al. Structure-guided design of a high affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg 2+ binding to the MIDAS. Science Translational Medicine 2012; 4: 1–12.
Coller, BS. Alphaiibbeta3: structure and function. Journal of Thrombosis and Haemostasis 2015; 13 Suppl 1: S17–25.
Aster, RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127: 53S–59S.
Bougie, DW, et al. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIbβ3 integrin. Blood 2012; 119: 6317–6325.
Brassard, JA, et al. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thrombosis and Haemostasis 2002; 88: 892–897.
Cox, D. Oral GPIIb/IIIa antagonists: what went wrong? Current Pharmaceutical Design 2004; 10: 1587–1596.
Chew, DP, et al. Increased mortality with oral glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201–206.
Chew, DP, Bhatt, DL, Topol, EJ. Oral glycoprotein IIb/IIIa inhibitors: why don’t they work? American Journal of Cardiovascular Drugs 2001; 1: 421–428.
Bhalla, MC, et al. Predictors of epinephrine autoinjector needle length inadequacy. The American Journal of Emergency Medicine 2013; 31: 1671–1676.
Song, TT. Epinephrine needle length in autoinjectors and why it matters. The Journal of Allergy and Clinical Immunology. In practice 2018; 6: 1264–1265.
Perina, D, Braithwaite, S. Acute myocardial infarction in the prehospital setting. Emergency Medicine Clinics of North America 2001; 19: 483–492.
O’Gara, PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362–425.
Phillips, DR, et al. Effect of Ca 2+ on GPIIb-IIIa interactions with integrilin: enhanced GPIIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calicum in plasma anticoagulated with citrate. Circulation 1997; 96: 1488–1494.
Mousa, SA, et al. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels. Cardiovascular Research 2000; 47: 819–826.
Marciniak, SJ Jr., Jordan, RE, Mascelli, MA. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thrombosis and Haemostasis 2001; 85: 539–543.
Kereiakes, DJ, et al. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. Journal of Thrombosis and Thrombolysis. 2001; 12: 123–127.
Jiang, JK, et al. A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor. Bioorganic & Medicinal Chemistry Letters 2014; 24: 1148–1153.
Shattil, SJ, et al. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. Journal of Biological Chemistry 1985; 260: 11107–11114.
De Luca, G, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293: 1759–1765.
Jollis, JG, et al. Impact of regionalization of ST-segment-elevation myocardial infarction care on treatment times and outcomes for emergency medical services-transported patients presenting to hospitals with percutaneous coronary intervention: mission: lifeline accelerator-2. Circulation 2018; 137: 376–387.
Heestermans, AA, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thrombosis Research 2008; 122: 776–781.
Montalescot, G, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. The New England Journal of Medicine 2014; 371: 1016–1027.
Walser, M. Ion association. VI. Interactions between calcium, magnesium, inorganic phosphate, citrate and protein in normal human plasma. The Journal of Clinical Investigation 1961; 40: 723–730.
Zhu, J, et al. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell 2008; 32: 849–861.
Tcheng, JE, et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). The American Journal of Cardiology 2001; 88: 1097–1102.
Coller, BS, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. The Journal of Clinical Investigation 1983; 72: 325–338.
Coller, BS, et al. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783–786.
Coller, BS, et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation and blockade of GPIIb/IIIa receptors. Circulation 1989; 80: 1766–1774.
Gold, HK, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a dog model. Circulation 1988; 77: 670–677.
Grimes, SD, et al. A dose range finding and pharmacokinetics study of RUC-4 succinate alone and in combination with aspirin in nonhuman primates. The Toxicologist (supplement to Toxicologic Sciences) 2017: Abstract 1700.
Hebert, CD, et al. Dose range-finding toxicity study of RUC-4 succinate in mice. The Toxicologist (supplement to Toxicologic Sciences) 2017: Abstract 1701.